Would not surprise me - the sales cycle in Enterprise Health is notoriously long (as evidenced by any lack of current revenues in Australia despite TGA approval a long while ago) and any FDA clearance if granted (which is not FDA approval which is entirely different) is just the first step to commercialisation in the US. This will be a slow burner IMHO.
Would not surprise me - the sales cycle in Enterprise Health is...
Add AYA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
-0.015(6.52%) |
Mkt cap ! $16.92M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.0¢ | 21.5¢ | $9.021K | 40.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 186 | 1 |
View Market Depth
| Last trade - 13.37pm 21/06/2024 (20 minute delay) ? |
| AYA (ASX) Chart |